Free Newsletter
Whistleblowers allege problems with Wyeth's Prevnar
Two former Wyeth workers continue to cause controversy for Wyeth's blockbuster vaccine Prevnar. Wyeth disclosed recently that the workers' whistleblower suits accused the company of making false statements to the government concerning manufacturing problems with the vaccine.
Anthony Sokol, a manufacturing scientist, says he was fired after raising concerns regarding the vaccine and that Wyeth had concealed and misrepresented the data it gave to the government. Sokol's suit alleges he was fired in 2005. Prevnar earned $2.4 billion in sales last year.
- read the report from the Wall Street Journal
Related Article:
Pharma execs practice positive thinking. Report
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
SHARE
WITH: